Bryce Point Capital LLC bought a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 96,550 shares of the company's stock, valued at approximately $1,142,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of ROIV. GAMMA Investing LLC increased its position in Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after acquiring an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after purchasing an additional 1,507 shares during the period. Quarry LP increased its position in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company's stock valued at $87,000 after purchasing an additional 2,500 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Roivant Sciences by 550.1% in the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock worth $91,000 after purchasing an additional 6,667 shares during the period. Finally, HighTower Advisors LLC purchased a new position in shares of Roivant Sciences in the fourth quarter worth approximately $121,000. 64.76% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on ROIV shares. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th.
Get Our Latest Analysis on Roivant Sciences
Roivant Sciences Stock Up 1.8 %
NASDAQ ROIV traded up $0.17 during trading hours on Tuesday, reaching $9.43. The company's stock had a trading volume of 1,664,542 shares, compared to its average volume of 5,332,270. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The company has a market capitalization of $6.73 billion, a price-to-earnings ratio of -62.95 and a beta of 1.25. The firm's 50-day moving average price is $10.58 and its 200-day moving average price is $11.31.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities research analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Insider Transactions at Roivant Sciences
In other news, COO Eric Venker sold 218,041 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total value of $2,271,987.22. Following the sale, the chief operating officer now owns 896,869 shares of the company's stock, valued at approximately $9,345,374.98. This represents a 19.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the company's stock in a transaction that occurred on Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 1,395,541 shares of company stock valued at $15,028,538. 7.90% of the stock is currently owned by insiders.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
